Compare UFPT & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | VIR |
|---|---|---|
| Founded | 1963 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1996 | 2019 |
| Metric | UFPT | VIR |
|---|---|---|
| Price | $188.61 | $10.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $289.00 | $19.43 |
| AVG Volume (30 Days) | 159.7K | ★ 1.7M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.44 | ★ 17.49 |
| EPS | ★ 8.75 | N/A |
| Revenue | ★ $602,797,000.00 | $68,556,000.00 |
| Revenue This Year | $8.12 | $270.22 |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $20.99 | ★ N/A |
| Revenue Growth | ★ 19.50 | N/A |
| 52 Week Low | $182.87 | $4.16 |
| 52 Week High | $274.93 | $11.66 |
| Indicator | UFPT | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 54.72 |
| Support Level | $185.32 | $8.47 |
| Resistance Level | $206.62 | $10.29 |
| Average True Range (ATR) | 8.91 | 0.54 |
| MACD | -0.38 | -0.05 |
| Stochastic Oscillator | 25.69 | 45.38 |
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.